FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PARSHALL B LYNNE						2. Issuer Name and Ticker or Trading Symbol IONIS PHARMACEUTICALS INC IONS IONS									applio Directo			10% Ov	vner		
(Last) (First) (Middle) C/O IONIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT						3. Date of Earliest Transaction (Month/Day/Year) 03/01/2017									X Officer (give title below) Other (specify below)						
(Street) CARLSBAD CA 92010 (City) (State) (Zip)					- 4. li	4. If Amendment, Date of Original Filed (Month/Day/Year)										Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - No	on-Deriv	vative	e Se	curit	ies Ac	quired	, Di	sposed o	of, or Be	neficia	lly Ov	vnec	I					
Date			Date	t. Transaction Date Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		ction nstr.		Securities Acquired (A) or posed Of (D) (Instr. 3, 4 a			and 5) Securiti Benefic Owned		Form (D) o	r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price	Tra		d tion(s) and 4)			(Instr. 4)		
Common Stock 03/01/2				/2017	017 03/01/201		/2017	M ⁽¹⁾		4,625(1)	A	\$14.6	i9	30,276			D				
Common Stock 03/01/2				/2017	2017 03/0		/2017	S ⁽¹⁾		4,625(1)	D	\$49.20	5 ⁽²⁾ 25		5,651		D				
		7	able II								oosed of converti			y Owr	ned			,	-		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deer Execution if any (Month/E		4. Transa Code (8)		ion of		6. Date E Expiratio (Month/D	n Dat		e Amount o		8. Prio Deriva Secur (Instr.	ative ity	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	i C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares								
Employee Stock Option (right to	\$14.69	03/01/2017	03/01	./2017	М			4,625	01/02/20	17	01/29/2020	Common Stock	4,625	\$()	7,785		D			

Explanation of Responses:

- 1. Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$49.20 to \$49.32, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Remarks:

buv)

/s/B. Lynne Parshall

03/02/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.